Oxford Technology is the specialist
in the start-up and early stage technology sector
Tax Shelter Report, Allenbridge

OT1 VCT has now Merged as a Separate Shareclass into OT2 VCT

All news will be reported on the Home Page.

Oxford Technology VCT was listed on the London Stock Exchange in April 1997. It raised £4.85m in 1997-98. Further top-up offers have raised a further £245k. The fund is now fully invested.

It became a separate class of OT2 VCT Plc on the 1st July 2022.

Dividends paid to 28 Feb 2020 total 55p per share, mainly resulting from the sales of Valid Information Systems, MET, and part of OT1's holding in Scancell.


Proposed Merger RNS

View Documents Relevant to Merger


The Key Information Document for OT VCT is available here:

OT1 Class KID




Arecor- Investment Information for OT1
Date of First Investment Jun 2021
Arecor- Investment Information for OT2
Date of First Investment Jul 2007
Arecor - Investment Information for OT3
Date of First Investment Jul 2007
Arecor - Investment Information for OT4
Date of First Investment Jul 2007

Arecor Limited became Arecor Therapeutics Plc and floated in June 2021. It is a leader in the development of innovative formulation technology that enables differentiated biopharmaceutical products. It has developed a proprietary, patent backed formulation technology platform that has been proven to stabilize a broad range of molecules as aqueous compositions. Many proteins, peptides and vaccines are too unstable in liquid form and/or at high concentrations to develop stable ready-to-use drugs and Arecor has overcome these challenges to significantly enhance the delivery of therapeutic medicines to patients.

Since inception in 2007, it has built a successful revenue generating business employing this technology to enable and differentiate biopharmaceuticals for a large cross section of the major pharmaceutical companies on a fee for service plus licensing model.

Arecor has taken the strategic decision to develop a portfolio of differentiated peptides through to clinical proof of concept, with an initial focus on diabetes as a therapeutic area. Arecor have announced three key products: an ultra-rapid acting insulin, a highly concentrated insulin and a stable aqueous glucagon.

Arecor has successfully defended two key European patents against active opposition which is an indicator of both the novelty of their work and the importance to potential competitors. Innovate UK backed the development of the super-fast-acting prandial insulin with a £500k grant.

Arecor is based at the Cambridge Science Park in the UK and has a highly talented scientific and management team.  



Bio Cote Logo

BioCote - Investment Information for OT1
Date of First Investment Dec 1997

BioCote is based in Wolverhampton and has developed a range of anti-microbial coatings. BioCote's business model is to license the use of its technology to manufacturers of products, which then gives built-in antimicrobial protection. The technology, which is based on silver, is supplied primarily to the healthcare, food and other hygiene conscious industries. BioCote aims to provide a full service to its customers. It supplies not only the anti-microbial surface or the ingredients with which to make it, but also training, help with regulatory issues, of which there are many, a full testing service, help with product launch and support at exhibitions.

BioCote’s anti-microbial surface is effective against MRSA and C.Diff, and the coating, in a variety of formulations, may be applied to all surfaces in hospitals (for example), including, floor, walls, ceiling, beds, furniture, bed linen, furniture etc. This provides a second line of defence against infection, the first being provided by what should be normal hygiene and cleaning regimes.



Getmapping- Investment Information for OT1
Date of First Investment Mar 1999

OT1 was the first investor in Getmapping when the company was founded in 1999. The company was formed to make the first complete aerial photograph of the UK, known as the Millennium Map.

Critical to Getmapping’s business plan was that Ordnance Survey had no interest in aerial photography as a product, and had signed an agreement with Getmapping under which it would re-sell the Millennium Map to local and central government users. But in 2001, after the company had raised £10m on AIM, OS terminated the reseller agreement and started to develop its own rival product. This was a devastating blow to Getmapping, which took court action against OS. But in the event, Getmapping did not have enough capital to see the case through. Getmapping had to drastically downsize and came close to going bankrupt. The share price fell and the company delisted to save costs.

However, Getmapping persevered and the business survived and has prospered. The business now has numerous different strands, so that it is less dependent on any one of them than was once the case. For example, in an attempt to become less dependent on the UK, Getmapping is becoming a significant supplier of aerial photography and mapping services in Africa, which despite its many problems is now growing fast, and has a large need for current aerial survey services to support its growing infrastructure programs and resource exploitation.

Queens College - Oxford

Scancell Ltd


Scancell- Investment Information for OT1
Date of First Investment Aug 1999
Scancell- Investment Information for OT3
Date of First Investment Dec 2003
Scancell- Investment Information for OT2
Date of First Investment April 2018

Scancell is an AIM listed biotechnology company in which Oxford Technology VCT was one of the original investors in 1999 when Professor Lindy Durrant, Scancell’s founder was based in a university lab in Nottingham.

Scancell is developing novel immunotherapies for cancer based on two platform technologies, known as ImmunoBody and Moditope. Scancell’s first ImmunoBody, SCIB1 is being developed for the treatment of melanoma and is in Phase II clinical trials. In theory, these Scancell technologies could be used to treat many common forms of cancer, including breast and prostate. Data from the trials to date is encouraging and demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

Scancell remains a high risk investment – clinical trials can go either way, but if the trials go well, we would expect to see a significant increase in the share price. The whole area of cancer immunology is now centre stage for major pharmaceutical companies seeking to secure a long term position, as this very new exciting area starts to deliver excellent clinical outcomes, which are anticipated to replace current crude, but often effective, treatments based around chemotherapy and radiotherapy.

New data published in March 2015 demonstrated that animals treated with a combination of SCIB2, Scancell's ImmunoBody® vaccine in development for the treatment of lung, oesophageal, prostate and other epithelial cancers, and checkpoint inhibition showed enhanced tumour destruction and significantly longer survival times than when either treatment was used alone which is positive news.

Scancell Holdings is listed in the FTSE AIM All-Share Index in the Pharmaceuticals & Biotechnology sector. (Code SCLP)

Click here for Scancell shareprice information

Select Technology Ltd


Select Technology- Investment Information for OT1
Date of First Investment Sep 1999
Select Technology- Investment Information for OT2
Date of First Investment Nov 2001
Select Technology- Investment Information for OT3
Date of First Investment Nov 2004
Select Technology- Investment Information for OT4
Date of First Investment Aug 2006

Select Technology (STL Management Ltd) distributes high quality document management software via its global channel partners while adding significant further value through its development team by providing integrations or bespoke solutions. Select Technology grew significantly between 2010 and 2018 by focusing on print management software, primarily PaperCut. Realising that this type of software has become increasingly commoditised, the company changed its focus to document capture and sharing, acquiring distribution rights to additional software solutions and introducing them to the market in an innovative way

Select Technology has also been a leading light in the formation of IDEA – the International Document Evolution Alliance. The founder members of the Alliance are all software specialists and able to provide a very high level of support for the products which they distribute. Each member is located in a separate geographical region and, between them, the members cover over 100 countries. This allows members to compete with major companies in attracting international business which, individually, they would not be able to do.

In addition, if an Alliance member encounters a new product for the document management market with significant potential, the member can bring it to the attention of IDEA. Given the combined purchasing power and expertise of the group, the Alliance can look to negotiate international distribution rights by offering the vendor an easy route to global distribution. The products which Select Technology distributes include Drivve Image, Everyone Print, Foldr, KPAX Management, Papercut and Square 9 content management.

Payment system at Cardiff University

Share Price Information and RNS Announcements

For information from the London Stock Exchange on the share price for OT1 and all RNS announcements, please click on the image below: